(The Translational Genomics Research Institute) An article in the journal Cell by top scientists from the Translational Genomics Research Institute (TGen) and Mayo Clinic in Arizona details how two relatively new drugs are helping patients with basal cell carcinoma. Basal cell carcinoma is the most common type of skin cancer, producing nearly 2.8 million new cases annually in the US, and sunny Arizona has one of the world’s highest incidences of skin cancer.

Related Links:

(Stanford Medicine) People who develop abnormally frequent cases of a skin cancer known as basal cell carcinoma appear to be at significantly increased risk for the development of other cancers, including blood, breast, colon and prostate cancers, according to a preliminary study by researchers at the Stanford University School of Medicine.

ConclusionAggressive SCC should be suspected in cases of persistent and relapsing purulent lesions in all patients.

Basal cell carcinoma (BCC), the most common type of skin cancer, accounts for at least 32% of all cancers globally with an incidence that continues to rise. Currently, suspected BCCs are diagnosed initially with partial biopsy, requiring patients to return to clinic for treatment. Treatment depends on the anatomic location, size, and histologic subtype of the tumor, with surgical options including electrodessication and curettage, excision, and Mohs micrographic surgery. In light of the rising incidence of BCC, separate clinic visits for diagnosis and treatment amplify the increasing demand for dermatology services.

Basal cell carcinoma (BCC) is the most common cancer in the United States. The prognosis and treatment protocol for BCC, among other factors, is dependent on the tumor subtype, which can be superficial, nodular/micronodular, or infiltrative. Diagnosis of tumor subtype is made typically on a clinical basis and is supported histologically by either punch or shave tissue biopsy. The agreement between histologic BCC subtype on initial punch biopsy versus after surgical reexcision may be as low as 60.9%.

Skin cancer is the most common malignancy in the white population worldwide. It is divided into melanoma and nonmelanoma skin cancer (NMSC). Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are the most common subtypes of NMSC and it is estimated that 2-3 million new cases occur globally each year. Malignant melanoma is the least common skin cancer; however, it is the most fatal one its incidence is alarmingly increasing. According to worldwide trends, skin cancer is the most prevalent malignancy in Colombia, by 2010 reached up to 20.2% of all cancer cases attended.

Background: While most basal cell skin cancer (BCC) develops in older individuals, the incidence of BCC in both women and men

Introduction: Basal cell carcinoma (BCC) is the most frequent cancer worldwide. There are more than 30 histopathologic subtypes; however, the nodular type is the commonest. Pigmented variants are common in darker skin types. There is an increased number and size of melanocytes, and melanogenesis is increased by hyperfunctioning melanocytes. However, the molecular features that distinguish each variant, and its possible physiopathologic implications have not been studied.

Perineural invasion (PNI) is a mechanism of neoplastic growth and spread that occurs in and around nerves as a means of minimal resistance. Squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) are among the most common cutaneous tumors known to take advantage of this phenomenon. Moreover, tumors that exhibit PNI are at higher risk for distant metastases, and are associated with an increased rate of recurrence, morbidity, and mortality. The link between PNI and invasive techniques such as cryosurgery has been proposed, but studies are limited.

Rationale: Basal cell carcinoma (BCC), a form of nonmelanoma skin cancer (NMSC), is the most common malignancy in the United States, and its incidence is increasing annually. While mortality is low, BCC can have significant morbidity as they become locally aggressive with substantial cosmetic deformities. The current criterion standard is diagnosis via histopathologic evaluation, and subsequent surgical removal of the skin cancer. Because NMSC frequently occur on the head and neck, these procedures often lead to visibly undesirable scars and/or functional impairment.

Introduction: Approximately 3 million Americans are diagnosed and treated annually with nonmelanoma skin cancer (NMSC), including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Traditionally these cancers are diagnosed by shave biopsy or punch biopsy. Although shave biopsy is often used in diagnosis of NMSC, limited data exists regarding the persistence of residual tumor at the time of definitive treatment, such as excision. Literature suggests that 15%-40% of the time residual NMSC is not found at the time of excision following shave biopsy.

Source link


Please enter your comment!
Please enter your name here

Enter Captcha Here : *

Reload Image